Unintended impacts of a medicaid prior authorization policy on access to medications for bipolar illness

Medical Care

Volumn 48, Issue 1, 2010, Pages 4-9

  Lu, Christine Y ^a,b   Soumerai, Stephen B ^a   Ross Degnan, Dennis ^a   Zhang, Fang ^a   Adams, Alyce S ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^c DIVISION OF RESEARCH   (United States)

Author keywords

Bipolar disorder; Interrupted time series; Medicaid; Medication access; Prior authorization

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; LITHIUM; VALPROIC ACID;

ADULT; AGED; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; FEMALE; HEALTH CARE POLICY; HUMAN; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; MENTAL DISEASE;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; COST CONTROL; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; GATEKEEPING; HEALTH SERVICES ACCESSIBILITY; HUMANS; INSURANCE CLAIM REVIEW; MAINE; MEDICAID; MIDDLE AGED; NEW HAMPSHIRE; REIMBURSEMENT MECHANISMS; TIME FACTORS; UNITED STATES; YOUNG ADULT;

EID: 73949153976     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLR.0b013e3181bd4c10     Document Type: Article

References (30)

1. Smith C, Cowan C, Heffler S, et al. National health spending in 2004: recent slowdown led by prescription drug spending. Health Aff. 2006; 25:186-196
2. Catlin A, Cowan C, Heffler S, et al. National Health Expenditure Accounts Team. National health spending in 2005: the slowdown continues. Health Aff. 2007;26:142-153
3. Crowley JS, Ashner D, Elam L. State Medicaid Outpatient Prescription Drug Policies: Findings From a National Survey, 2005 Update. Washington, DC: Kaiser Commission on Medicaid and the Uninsured, Kaiser Family Foundation; 2005
4. Huskamp HA, Stevenson DG, Donohue JM, et al. Coverage and prior authorization of psychotropic drugs under Medicare Part D. Psychiatr Serv. 2007;58:308-310
5. Soumerai SB. Benefits and risks of increasing restrictions on access to costly drugs in Medicaid. Health Aff (Millwood). 2004;23:135-146
6. Adams AS, Zhang F, LeCates R, et al. Prior authorization for antide-pressants in Medicaid: effects among disabled dual enrollees. Arch Intern Med. 2009;169:750-756
7. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002;159: 1-50
8. Koyanagi C, Forquer S, Alfano E. Medicaid policies to contain psychiatric drug costs. Health Aff. 2005;24:536
9. Soumerai SB, Zhang F, Ross-Degnan D, et al. Use of atypical antipsy-chotic drugs for schizophrenia in Maine Medicaid following a policy change. Health Aff. 2008;27:w185-w195
10. Zhang Y, Adams AS, Ross-Degnan D, et al. Effects of prior authorization on medication discontinuation among Medicaid beneficiaries with bipolar disorder. Psychiatr Serv. 2009;60:520-527
11. Saucier P, Benzanson L, Booth M, et al. Linked data analysis of dually eligible beneficiaries in New England. Health Care Financ Rev. 1998; 20:91-108
12. Busch AB, Ling D, Frank RG, et al. Changes in the quality of care for bipolar I disorder during the 1990s. Psychiatr Serv. 2007;58:27-33
13. Wagner AK, Soumerai SB, Zhang F, et al. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27:299-309
14. Gillings D, Makuc D, Siegel E. Analysis of interrupted time series mortality trends: an example to evaluate regionalized perinatal care. Am J Public Health. 1981;71:38-46
15. Kleinbaum DG, Kupper LL, Muller KE, et al. Applied Regression Analysis and Other Multivariable Methods. Pacific Grove, CA: Duxbury Press; 1998
16. Diggle PJ, Heagerty P, Liang KY, et al. Analysis of Longitudinal Data. Oxford, United Kingdom: Oxford University Press; 2002
17. Fitzmaurice GM, Laird NM, Ware JH. Applied Longitudinal Analysis. Hoboken, NJ: John Wiley & Sons; 2004
18. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epide-miologic studies using claims data. Am J Epidemiol. 2001;154:854-864
19. Soumerai SB, McLaughlin TJ, Ross-Degnan D, et al. Effects of limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med. 1994;331:650-655
20. Wagner A, Ross-Degnan D, Gurwitz JH, et al. Effect of New York state regulatory action on benzodiazepine prescribing and hip fracture rates. Ann Intern Med. 2007;146:96-103
21. Zhang F, Wagner A, Soumerai SB, et al. Methods for estimating confidence intervals in interrupted time series analyses of health interventions J Clin Epidemiol. 2009;62:143-148
22. MacKinnon NJ, Kumar R. Prior authorization programs: a critical review of the literature. J Manag Care Pharm. 2001;7:297-302
23. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-497
24. Bowden CL, Krishnan AA. Pharmacotherapy for bipolar depression: an economic assessment. Expert Opin Pharmacother. 2004;5:1101-1107
25. MaineCare Advisory Committee's Prior Authorization Subcommittee Report and Recommendations on Prior Authorization for Prescription Drugs in the MaineCare and Drugs for the Elderly Programs, submitted to the Maine Department of Health and Human Services, Augusta, Maine, 19 January 2005
26. Law MR, Ross-Degnan D, Soumerai SB. Effect of prior authorization of second-generation antipsychotic agents on pharmacy utilization and reimbursements. Psychiatr Serv. 2008;59:540-546
27. Fischer MA, Schneeweiss S, Avorn J, et al. Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors. N Eng J Med. 2004;351:2187-2194
28. Roughead EE, Zhang F, Ross-Degnan D, et al. Differential effect of early or late implementation of prior authorization policies on the use of Cox II inhibitors. Med Care. 2006;44:378-382
29. Smalley WE, Griffin MR, Fought RL, et al. Effect of a prior-authorization requirement on the use of nonsteroidal anti-inflammatory drugs by Medicaid patients. N Engl J Med. 1995;332:1612-1617
30. Delate T, Mager DE, Sheth J, et al. Clinical and financial outcomes associated with a proton pump inhibitor prior-authorization program in a Medicaid population. Am J Manag Care. 2005;11:29-36